新辅助化疗下保留乳房治疗T_2期乳腺癌的疗效及安全性

Efficacy and safety of breast-conserving surgery with neoadjuvant chemotherapy for T_2 stage breast cancer

目的研究新辅助化疗下保乳术治疗T2期乳腺癌的疗效和安全性。方法选取我院2011—2015年收治的106例T2期乳腺癌患者为研究对象,采用随机数字表法将其分为对照组(n=53)和观察组(n=53),对照组予以常规乳腺癌改良根治切除术,并术后辅助放、化疗,而观察组则予以新化疗辅助联合保留乳房手术,术后均对两组患者随访两年,比较两组的治疗效果及安全性。结果观察组患者的手术时间、住院时间均显著短于对照组,平均引流量显著少于对照组(P<0.05);观察组术后出血发生率、术后2年复发率、术后2年肿瘤远处转移率均显著低于对照组(P<0.05);观察组的实体瘤治疗效果显著优于对照组(P<0.05)。结论新辅助化疗下保乳术较大程度上提高了T2期乳腺癌患者的生存率,安全性及患者满意度均较高。

Objective To study the efficacy and safety of breast-conserving surgery with neoadjuvant chemotherapy inthe treatment ofT2 stage breast cancer. Methods A total of 106 patients withT2 stage breast cancer were selected asstudy objects from 2011 to 2015, they were divided into control group （n=53） and observation group （n=53）, the controlgroup was treated with routine modified radical mastectomy and postoperative adjuvant radiotherapy and chemotherapy,the observation group was treated with breast -conserving surgery with neoadjuvant chemotherapy. Both groups werefollowed up for 2 years after surgery, the treatment effects and safeties of the two groups were compared. Results Theoperation time and hospitalization time of the observation group were significantly shorter than those of the control group,and the average drainage volume was significantly less than that of the control group （P〈0.05）. The incidence ofpostoperative bleeding, the recurrence rate and the distant metastasis rate of the tumor after 2 years of surgery in theobservation group were significantly lower than those in the control group （P〈0.05）. The solid tumor treatment effect ofthe observation group was significantly better than that of the control group （P〈0.05）. Conclusion Breast-conservingsurgery with neoadjuvant chemotherapy greatly improves the survival rate of patients withT2 stage breast cancer, and thesafety and patient＇s satisfaction are higher.